Rockwell Medical price target raised to $11 from $9 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Rockwell Medical to $11 from $9 and keeps a Buy rating on the shares. The company’s acquisition of the hemodialysis concentrates business from privately-held Evoqua Water Technologies is immediately accretive and poised to boost revenue, the analyst tells investors in a research note. The firm says the transaction should broaden Rockwell’s geographic reach in the U.S. and increase revenue in an immediately accretive manner. It says Rockwell is poised to become the leading supplier of liquid bicarbonate products to U.S. dialysis centers upon the closing of this transaction.